v3.26.3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit (Unaudited) - USD ($)
Total
Series F convertible preferred stock warrants
Convertible Preferred Stock
Convertible Preferred Stock
Series F convertible preferred stock warrants
Convertible Preferred Stock
Series E-1 And Series F Convertible Preferred Stock
Convertible Preferred Stock Held by Consolidated VIE
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024     209,613,570     51,247,915        
Beginning balance at Dec. 31, 2024     $ 322,748,000     $ (2,381,000)        
Ending balance (in shares) at Mar. 31, 2025     209,613,570     51,247,915        
Ending balance at Mar. 31, 2025     $ 322,748,000     $ (2,381,000)        
Beginning balance (in shares) at Dec. 31, 2024             82,642,684      
Beginning balance at Dec. 31, 2024 $ (504,685,000)           $ 300,000 $ (23,417,000) $ 162,643,000 $ (644,211,000)
Beginning balance (in shares) at Dec. 31, 2024               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             127,206      
Exercise of vested stock options 7,000           $ 1,000   6,000  
Stock-based compensation expense 416,000               416,000  
Net income (loss) 50,375,000                 50,375,000
Ending balance (in shares) at Mar. 31, 2025             82,769,890      
Ending balance at Mar. 31, 2025 (453,887,000)           $ 301,000 $ (23,417,000) 163,065,000 (593,836,000)
Ending balance (in shares) at Mar. 31, 2025               (5,177,235)    
Beginning balance (in shares) at Dec. 31, 2024     209,613,570     51,247,915        
Beginning balance at Dec. 31, 2024     $ 322,748,000     $ (2,381,000)        
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13) (in shares)       51,614,124            
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13)       $ 73,808,000            
Ending balance (in shares) at Sep. 30, 2025     261,227,694     51,247,915        
Ending balance at Sep. 30, 2025     $ 396,556,000     $ (2,381,000)        
Beginning balance (in shares) at Dec. 31, 2024             82,642,684      
Beginning balance at Dec. 31, 2024 (504,685,000)           $ 300,000 $ (23,417,000) 162,643,000 (644,211,000)
Beginning balance (in shares) at Dec. 31, 2024               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             722,826      
Exercise of vested stock options 44,000           $ 7,000   37,000  
Stock-based compensation expense 1,206,000               1,206,000  
Net income (loss) (36,844,000)                 (36,844,000)
Ending balance (in shares) at Sep. 30, 2025             83,365,510      
Ending balance at Sep. 30, 2025 (540,279,000)           $ 307,000 $ (23,417,000) 163,886,000 (681,055,000)
Ending balance (in shares) at Sep. 30, 2025               (5,177,235)    
Beginning balance (in shares) at Mar. 31, 2025     209,613,570     51,247,915        
Beginning balance at Mar. 31, 2025     $ 322,748,000     $ (2,381,000)        
Ending balance (in shares) at Jun. 30, 2025     209,613,570     51,247,915        
Ending balance at Jun. 30, 2025     $ 322,748,000     $ (2,381,000)        
Beginning balance (in shares) at Mar. 31, 2025             82,769,890      
Beginning balance at Mar. 31, 2025 (453,887,000)           $ 301,000 $ (23,417,000) 163,065,000 (593,836,000)
Beginning balance (in shares) at Mar. 31, 2025               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             190,900      
Exercise of vested stock options 10,000           $ 2,000   8,000  
Stock-based compensation expense 430,000               430,000  
Net income (loss) (57,727,000)                 (57,727,000)
Ending balance (in shares) at Jun. 30, 2025             82,960,790      
Ending balance at Jun. 30, 2025 (511,174,000)           $ 303,000 $ (23,417,000) 163,503,000 (651,563,000)
Ending balance (in shares) at Jun. 30, 2025               (5,177,235)    
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13) (in shares)       51,614,124            
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13)       $ 73,808,000            
Ending balance (in shares) at Sep. 30, 2025     261,227,694     51,247,915        
Ending balance at Sep. 30, 2025     $ 396,556,000     $ (2,381,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             404,720      
Exercise of vested stock options 27,000           $ 4,000   23,000  
Stock-based compensation expense 360,000               360,000  
Net income (loss) (29,492,000)                 (29,492,000)
Ending balance (in shares) at Sep. 30, 2025             83,365,510      
Ending balance at Sep. 30, 2025 $ (540,279,000)           $ 307,000 $ (23,417,000) 163,886,000 (681,055,000)
Ending balance (in shares) at Sep. 30, 2025               (5,177,235)    
Beginning balance (in shares) at Dec. 31, 2025 261,227,694   261,227,694     51,247,915        
Beginning balance at Dec. 31, 2025     $ 396,556,000     $ (2,381,000)        
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13) (in shares)         77,378,045          
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13)         $ 81,770,000          
Ending balance (in shares) at Mar. 31, 2026     338,605,739     51,247,915        
Ending balance at Mar. 31, 2026     $ 478,326,000     $ (2,381,000)        
Beginning balance (in shares) at Dec. 31, 2025 78,202,775           83,380,010      
Beginning balance at Dec. 31, 2025 $ (538,783,000)           $ 307,000 $ (23,417,000) 164,240,000 (679,913,000)
Beginning balance (in shares) at Dec. 31, 2025               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             96,580      
Exercise of vested stock options 2,000               2,000  
Stock-based compensation expense 521,000               521,000  
Net income (loss) 64,651,000                 64,651,000
Ending balance (in shares) at Mar. 31, 2026             83,476,590      
Ending balance at Mar. 31, 2026 $ (473,609,000)           $ 307,000 $ (23,417,000) 164,763,000 (615,262,000)
Ending balance (in shares) at Mar. 31, 2026               (5,177,235)    
Beginning balance (in shares) at Dec. 31, 2025 261,227,694   261,227,694     51,247,915        
Beginning balance at Dec. 31, 2025     $ 396,556,000     $ (2,381,000)        
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13) (in shares)         161,045,853          
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13)         $ 172,967,000          
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) (in shares)           (113,560)        
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13)           $ (69,000)        
Return of Convertible Preferred Stock from investor (Note 13) (in shares)     (289,560)              
Return of Convertible Preferred Stock from investor (Note 13)     $ (152,000)              
Ending balance (in shares) at Sep. 30, 2026 421,983,987 177,115,839 421,983,987     51,361,475        
Ending balance at Sep. 30, 2026     $ 569,371,000     $ (2,450,000)        
Beginning balance (in shares) at Dec. 31, 2025 78,202,775           83,380,010      
Beginning balance at Dec. 31, 2025 $ (538,783,000)           $ 307,000 $ (23,417,000) 164,240,000 (679,913,000)
Beginning balance (in shares) at Dec. 31, 2025               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             1,229,353      
Exercise of vested stock options 33,000           $ 11,000   22,000  
Cashless exercise of common stock warrants (Note 13) (in shares)             503,821      
Cashless exercise of common stock warrants (Note 13) 0           $ 5,000   (5,000)  
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) (in shares)             (244,130)      
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) 69,000               (133,000) 202,000
Return of Convertible Preferred Stock from investor (Note 13) 152,000                 152,000
Stock-based compensation expense 1,243,000               1,243,000  
Net income (loss) $ 112,758,000                 112,758,000
Ending balance (in shares) at Sep. 30, 2026 79,935,949           84,869,054      
Ending balance at Sep. 30, 2026 $ (424,528,000)           $ 323,000 $ (23,417,000) 165,367,000 (566,801,000)
Ending balance (in shares) at Sep. 30, 2026               (5,177,235)    
Beginning balance (in shares) at Mar. 31, 2026     338,605,739     51,247,915        
Beginning balance at Mar. 31, 2026     $ 478,326,000     $ (2,381,000)        
Increase (Decrease) in Temporary Equity [Roll Forward]                    
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13) (in shares)       83,667,808            
Exercise of Series E-1 and F convertible preferred stock warrants (Note 13)       $ 91,197,000            
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) (in shares)           (113,560)        
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13)           $ (69,000)        
Return of Convertible Preferred Stock from investor (Note 13) (in shares)     (289,560)              
Return of Convertible Preferred Stock from investor (Note 13)     $ (152,000)              
Ending balance (in shares) at Jun. 30, 2026     421,983,987     51,361,475        
Ending balance at Jun. 30, 2026     $ 569,371,000     $ (2,450,000)        
Beginning balance (in shares) at Mar. 31, 2026             83,476,590      
Beginning balance at Mar. 31, 2026 (473,609,000)           $ 307,000 $ (23,417,000) 164,763,000 (615,262,000)
Beginning balance (in shares) at Mar. 31, 2026               (5,177,235)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Exercise of vested stock options (in shares)             1,132,773      
Exercise of vested stock options 31,000           $ 11,000   20,000  
Cashless exercise of common stock warrants (Note 13) (in shares)             503,821      
Cashless exercise of common stock warrants (Note 13) 0           $ 5,000   (5,000)  
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) (in shares)             (244,130)      
Purchase of Convertible Preferred Stock and Common Stock by consolidated VIE Prosper Grantor Trust (Note 13) 69,000               (133,000) 202,000
Return of Convertible Preferred Stock from investor (Note 13) 152,000                 152,000
Stock-based compensation expense 378,000               378,000  
Net income (loss) 6,381,000                 6,381,000
Ending balance (in shares) at Jun. 30, 2026             84,869,054      
Ending balance at Jun. 30, 2026 $ (466,598,000)           $ 323,000 $ (23,417,000) 165,023,000 (608,527,000)
Ending balance (in shares) at Jun. 30, 2026               (5,177,235)    
Ending balance (in shares) at Sep. 30, 2026 421,983,987 177,115,839 421,983,987     51,361,475        
Ending balance at Sep. 30, 2026     $ 569,371,000     $ (2,450,000)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense $ 344,000               344,000  
Net income (loss) $ 41,726,000                 41,726,000
Ending balance (in shares) at Sep. 30, 2026 79,935,949           84,869,054      
Ending balance at Sep. 30, 2026 $ (424,528,000)           $ 323,000 $ (23,417,000) $ 165,367,000 $ (566,801,000)
Ending balance (in shares) at Sep. 30, 2026               (5,177,235)